HMB HEX OCT Ligands PPARα Activation Synaptic Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of understanding about endogenous ligands of PPARα in the hippocampus that modulate synaptic activity, which is crucial for regulating synaptic function and treating disorders such as dementia and neurological conditions.
Innovation Solution
Identification of three unique ligands, 3-hydroxy-(2,2)-dimethyl butyrate (HMB), hexadecanamide (HEX), and 9-Octadecenamide (OCT), which interact with PPARα in the hippocampus, activating it and upregulating synaptic functions, and their potential use in treating diseases like dementia and neurological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If affinity purification and GCMS analysis are performed to identify endogenous ligands of PPARα, then the understanding of synaptic function regulation is improved, but the complexity and cost of the research methodology increases
Solution Approach 1:
The patent extracts and identifies specific endogenous ligands (HMB, HEX, OCT) from complex hippocampal nuclear extracts using affinity purification with GST-PPARα. This extraction approach isolates the relevant ligand information from the complex biological mixture, resolving the contradiction between gaining understanding and methodological complexity.
Solution Approach 2:
The patent uses GST-PPARα fusion protein as an intermediary to capture and identify endogenous ligands. This intermediary molecule facilitates the detection of ligand-protein interactions without requiring direct observation of the complex nuclear receptor-ligand dynamics, thus improving understanding while managing methodological complexity.
2Measurement precision
If site-directed mutagenesis is performed on PPARα to confirm ligand binding residues, then the mechanistic understanding is improved, but the time and resources required increase
Solution Approach 1:
The patent performs site-directed mutagenesis on key residues (Tyr314, Tyr464) identified through computational modeling and structural analysis before conducting functional assays. This preliminary identification of candidate residues based on their structural importance accelerates the confirmation process, reducing the time required for mechanistic validation.
Solution Approach 2:
The patent systematically changes the chemical properties of specific amino acid residues through mutagenesis (e.g., hydroxyl group in Tyr to carboxyl group in Asp) to test their role in ligand binding. This parameter change approach provides precise mechanistic information about residue-ligand interactions while streamlining the experimental design.
3Reliability
If the focus is placed on identifying specific ligands for PPARα activation, then the therapeutic potential is improved, but the general applicability to other nuclear receptors decreases
Solution Approach 1:
The patent focuses on identifying ligands with specific molecular features that match the unique ligand-binding pocket characteristics of PPARα (e.g., preference for carboxylate and amide groups). This local quality approach optimizes therapeutic potential for PPARα-specific disorders while the identified ligand classes may still provide insights for related nuclear receptors.
Solution Approach 2:
The patent identifies ligands from common metabolic pathways (fatty acid metabolism) that are universally present in mammalian systems. The identified ligands (HMB, HEX, OCT) represent a universal class of endogenous metabolites that could potentially interact with multiple nuclear receptors, maintaining some versatility while providing targeted therapeutic opportunities for PPARα.
Data Source
Figure 1A~1E
Figure 1F~1J
Figure 1K~2A
AI summary
Methods of modulating peroxisome proliferator-activated receptor α (PPARα) activity in a cell in a subject In need thereof are provided. The methods include administering an effective amount of a PPARα ligand to the subject where the PPARα ligand is selected from 3-hydroxy-2,2-dimethyl butyrate (HMB), hexadecananamide (HEX) and 9-octadecenamide (OCT), Methods of treating dementia, neurodegenerative disorders, lysosomal storage diseases and body weight disorders in a subject in need thereof are provided. The methods include administering an effective amount of a PPARα ligand to the subject.